Drug Type Autologous CAR-T |
Synonyms CCT301 59 |
Target |
Mechanism ROR2 inhibitors(Tyrosine-protein kinase transmembrane receptor ROR2 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Renal Cell Carcinoma | Phase 2 | CN | 26 Mar 2018 | |
Bladder Cancer | Phase 1 | CN | 16 May 2019 | |
Pancreatic Cancer | Phase 1 | CN | 16 May 2019 | |
Relapsed Solid Neoplasm | Phase 1 | CN | 16 May 2019 | |
Sarcoma | Phase 1 | CN | 16 May 2019 | |
Stomach Cancer | Phase 1 | CN | 16 May 2019 |